Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 9/20 | 0.69 |
| ▸ | SMO | Q99835 | 5/20 | 0.66 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316036 | 0.89 | ACLY (0.63) | ACLYSMOSUCNR1DHODHGRIK1 | |
| SCHEMBL2270596 | 0.89 | ACLY (0.70) | ACLYSUCNR1HDAC8HDAC6GRIK1 | |
| SCHEMBL2268003 | 0.87 | ACLY (0.67) | ACLYSMOSUCNR1HPGDDHODH | |
| SCHEMBL1308314 | 0.85 | GRIK1 (0.69) | CYP1A2HPGDCYP2C19GRIK1 | |
| SCHEMBL2272508 | 0.84 | ACLY (0.63) | ACLYSUCNR1DHODH | |
| SCHEMBL2272453 | 0.84 | ACLY (0.63) | ACLYSUCNR1HPGDDHODH | |
| SCHEMBL1514283 | 0.83 | HPGD (0.77) | SMOCYP1A2HPGDCYP2C19DHODH | |
| SCHEMBL5145099 | 0.83 | ACLY (0.61) | ACLYSUCNR1DHODH | |
| SCHEMBL2268189 | 0.83 | ACLY (0.61) | ACLYSUCNR1HPGDDHODH | |
| SCHEMBL28925309 | 0.82 | ACLY (0.64) | ACLYSUCNR1DHODHGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885SMO 1216/4885SUCNR1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.